

31 March 2021  
ASX Code: MXC  
LSE Code: MXC

## Results of General Meeting

A  
S  
X  
  
R  
E  
L  
E  
A  
S  
E

**MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company')**, would like to confirm the results of the Company's General Meeting held 31 March 2021 in accordance with Listing Rule 3.13.2. All resolutions put to the meeting were passed on a poll.

Details of the proxy and poll voting on the resolutions are set out in the attached report.

--Ends--

**Authorised for issue by Narelle Warren, Company Secretary, further information, please contact:**

**PR/IR Advisors – Media & Capital Partners**

Rod Hinchcliffe (IR) +61 412 277 377  
Rod.Hinchcliffe@mcpartners.com.au

**MGC Pharmaceuticals Ltd**

Roby Zomer  
CEO & Managing Director  
+61 8 6382 3390  
info@mgcpharma.com.au

**UK Broker – Turner Pope**

Andy Thacker  
Andy.Thacker@TurnerPope.com  
Zoe Alexander +44 20 3657 0050  
Zoe.Alexander@TurnerPope.com

**UK PR Advisors – Tavistock**

Charles Vivian +44 207 920 3150  
Charles.Vivian@tavistock.co.uk  
Tim Pearson +44 7983118 502  
Tim.Pearson@tavistock.co.uk

### About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels



**MGC PHARMACEUTICALS LTD**  
**General Meeting**  
**Wednesday, 31 March 2021**  
**Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Ratification of prior issue of LSE Placement Shares - Listing Rule 7.1	Ordinary	390,198,154 96.16%	11,280,253 2.78%	4,339,030 1.07%	3,168,864	394,537,184 97.22%	11,280,253 2.78%	3,168,864	Carried
2 Ratification of prior issue of LSE Placement Shares - Listing Rule 7.1A	Ordinary	390,165,319 96.18%	11,160,253 2.75%	4,371,865 1.07%	3,318,864	394,537,184 97.25%	11,160,253 2.75%	3,318,864	Carried
3 Ratification of prior issue of Adviser Shares	Ordinary	390,656,549 96.27%	10,809,085 2.66%	4,348,530 1.07%	3,252,137	395,005,079 97.34%	10,809,085 2.66%	3,252,137	Carried
4 Approval to issue Lead Manager Options	Ordinary	387,350,946 95.50%	13,886,970 3.42%	4,389,030 1.08%	3,439,355	391,739,976 96.58%	13,886,970 3.42%	3,439,355	Carried
5 Adoption of Incentive Plan	Ordinary	336,487,374 95.23%	12,457,934 3.53%	4,369,234 1.24%	45,660,850	340,856,608 96.47%	12,457,934 3.53%	45,660,850	Carried

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.